LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Clinical Application of Leukocyte Counts Based on Targeted DNA Methylation Analysis

By LabMedica International staff writers
Posted on 14 Mar 2022
Image: PyroMark Q96 ID instrument for quantitative analysis of genetic or epigenetic DNA modifications using Pyrosequencing technology (Photo courtesy of Karolinska Institutet)
Image: PyroMark Q96 ID instrument for quantitative analysis of genetic or epigenetic DNA modifications using Pyrosequencing technology (Photo courtesy of Karolinska Institutet)

Leukocyte subsets are usually quantified with automated cell counting devices and particularly for stratification of lymphocyte subsets with flow cytometry. Despite broad application, conventional methods have several limitations.

DNA methylation (DNAm) is a covalent modification of cytosine residues, mostly at CG dinucleotides (CpG sites). By measuring the methylation level at CpG sites with cell-type–specific hypo- or hypermethylation, it is possible to quantify the composition of leukocyte subsets using statistical algorithms (deconvolution models).

Biomedical Engineers at the RWTH Aachen University (Aachen, Germany) and colleagues optimized and validated targeted DNAm assays for leukocyte deconvolution using 332 venous and 122 capillary blood samples from healthy donors. In addition, they tested 36 samples from ring trials and venous blood from 266 patients diagnosed with different hematological diseases. Deconvolution of cell types was determined with various models using DNAm values obtained by pyrosequencing or digital droplet PCR (ddPCR).

DNA was isolated from 150 µL venous or 50 µL capillary blood and bisulfite-treated with the EZ DNA Methylation Kit (Zymo Research, Irvine, CA, USA). PCR amplicons were sequenced on a PyroMark Q96 ID (Qiagen, Hilden, Germany) and analyzed with Qiagen’s PyroMark Q96 CpG 1.0.9. Digital Droplet Polymerase Chain Reaction (ddPCR) was carried out with the QX200 Droplet Digital reader (Bio-Rad, Hercules, CA, USA). Absolute leukocyte quantification by pyrosequencing was also performed.

The investigators reported that relative leukocyte quantification correlated with conventional blood counts for granulocytes, lymphocytes, B cells, T cells (CD4 or CD8), natural killer cells, and monocytes with pyrosequencing and ddPCR measurements. In some patients, particularly with hematopoietic malignancies, they observed outliers in epigenetic leukocyte counts, which could be discerned if relative proportions of leukocyte subsets did not sum up to 100%. Furthermore, absolute quantification was obtained by spiking blood samples with a reference plasmid of known copy number. The results confirmed cell-type–specific hypomethylation in the genes WDR20, CD4, CD8A, WIPI2, SLC15A4, and CENPA, which was more pronounced compared to the Illumina BeadChip data or reverse nonnegative least square (NNLS) estimation.

The authors concluded that targeted DNAm analysis by pyrosequencing or ddPCR is a valid alternative to quantify leukocyte subsets, but some assays require further optimization. The study was published on February 14, 2022 in the journal Clinical Chemistry.

Related Links:
RWTH Aachen University 
Zymo Research 
Qiagen 
Bio-Rad 

 

 

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Urine Chemistry Control
Dropper Urine Chemistry Control

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more